Patents by Inventor Marc Lapierre

Marc Lapierre has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHOD FOR PREPARING CYCLOHEXYL THIAZOLYL PHENYL CARBAMATE
    Publication number: 20250051294
    Abstract: The present application relates to methods of preparing Compound A: or a pharmaceutically acceptable salt or solvate thereof.
    Type: Application
    Filed: August 9, 2024
    Publication date: February 13, 2025
    Inventors: Kuangchu DAI, Sebastien Pierre Louis ALAZET, Maxence Benjamin BOS, Felix CHAGNON, Jean-Marc LAPIERRE, Vu Linh LY, Bernhard Josef PAUL, Guangwei RONG
  • RAD51 INHIBITORS
    Publication number: 20240360120
    Abstract: This application is directed to inhibitors of RAD51 represented by the following structural formula, and methods for their use, such as to treat cancer, autoimmune diseases, immune deficiencies, or neurodegenerative diseases.
    Type: Application
    Filed: January 30, 2024
    Publication date: October 31, 2024
    Inventors: Jean-Marc LAPIERRE, Casey Cameron MCCOMAS, Joseph VACCA
  • RAD51 inhibitors
    Patent number: 11932636
    Abstract: This application is directed to inhibitors of RAD51 represented by the following structural formula, and methods for their use, such as to treat cancer, autoimmune diseases, immune deficiencies, or neurodegenerative diseases.
    Type: Grant
    Filed: December 16, 2021
    Date of Patent: March 19, 2024
    Assignee: Cyteir Therapeutics, Inc.
    Inventors: Jean-Marc Lapierre, Casey Cameron McComas, Joseph Vacca
  • RAD51 INHIBITORS
    Publication number: 20220259198
    Abstract: This application is directed to inhibitors of RAD51 represented by the following structural formula, and methods for their use, such as to treat cancer, autoimmune diseases, immune deficiencies, or neurodegenerative diseases.
    Type: Application
    Filed: December 16, 2021
    Publication date: August 18, 2022
    Inventors: Jean-Marc LAPIERRE, Casey Cameron MCCOMAS, Joseph VACCA
  • RAD51 inhibitors
    Patent number: 11247988
    Abstract: This application is directed to inhibitors of RAD51 represented by the following structural formula, and methods for their use, such as to treat cancer, autoimmune diseases, immune deficiencies, or neurodegenerative diseases.
    Type: Grant
    Filed: March 12, 2020
    Date of Patent: February 15, 2022
    Assignee: Cyteir Therapeutics, Inc.
    Inventors: Jean-Marc Lapierre, Casey Cameron McComas, Joseph Vacca
  • TARGETING HOMOLOGOUS RECOMBINATION: A NEW SYTHETIC LETHAL THERAPEUTIC PARADIGM
    Publication number: 20210275503
    Abstract: This application is directed to inhibitors of RAD51 represented by the following structural formula, and methods for its use, such as to treat cancer.
    Type: Application
    Filed: March 3, 2021
    Publication date: September 9, 2021
    Inventors: Thomas O'SHEA, Markus RENSCHLER, Todd BOWSER, Jean-Marc LAPIERRE, Kevin MILLS
  • Amino-pyrrolopyrimidinone compounds and methods of use thereof
    Patent number: 11020398
    Abstract: The application relates to a compound of Formula (I): or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, which modulates the activity of BTK, a pharmaceutical composition comprising a compound of Formula (I), and a method of treating or preventing a disease in which BTK plays a role.
    Type: Grant
    Filed: August 23, 2017
    Date of Patent: June 1, 2021
    Assignee: ArQule, Inc.
    Inventors: Craig Bates, Sudharshan Eathiraj, Hiroaki Inagaki, Jean-Marc Lapierre, Takayuki Momose, Kiyoshi Nakayama, Takashi Odagiri, Masahiro Ota, Yusuke Ota, Yoshihiro Shibata, Manish Tandon, Tomoyuki Tsunemi
  • Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof
    Patent number: 11020400
    Abstract: The application relates to a compound of Formula (I): or a pharmaceutically acceptable salt thereof, tautomer, prodrug, solvate, metabolite, polymorph, analog or derivative thereof, which modulates the activity of BTK, a pharmaceutical composition comprising the compound of Formula (I), and a method of treating or preventing a disease in which BTK plays a role.
    Type: Grant
    Filed: November 4, 2019
    Date of Patent: June 1, 2021
    Assignee: ArQule, Inc.
    Inventors: Jean-Marc Lapierre, Sudharshan Eathiraj, Nivedita Namdev, Brian Schwartz, Yusuke Ota, Takayuki Momose, Tomoyuki Tsunemi, Hiroaki Inagaki, Kiyoshi Nakayama
  • TETRAHYDROPYRANYL AMINO-PYRROLOPYRIMIDINONE AND METHODS OF USE THEREOF
    Publication number: 20210145837
    Abstract: The application relates to a compound of Formula (I): or a pharmaceutically acceptable salt thereof, tautomer, prodrug, solvate, metabolite, polymorph, analog or derivative thereof, which modulates the activity of BTK, a pharmaceutical composition comprising the compound of Formula (I), and a method of treating or preventing a disease in which BTK plays a role.
    Type: Application
    Filed: January 27, 2021
    Publication date: May 20, 2021
    Applicant: ArQule, Inc.
    Inventors: Jean-Marc Lapierre, Sudharshan Eathiraj, Nivedita Namdev, Brian Schwartz, Yusuke Ota, Takayuki Momose, Tomoyuki Tsunemi, Hiroaki Inagaki, Kiyoshi Nakayama
  • Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof
    Patent number: 10933065
    Abstract: The application relates to a compound of Formula (I): or a pharmaceutically acceptable salt thereof, tautomer, prodrug, solvate, metabolite, polymorph, analog or derivative thereof, which modulates the activity of BTK, a pharmaceutical composition comprising the compound of Formula (I), and a method of treating or preventing a disease in which BTK plays a role.
    Type: Grant
    Filed: March 4, 2019
    Date of Patent: March 2, 2021
    Assignee: ArQule Inc.
    Inventors: Jean-Marc Lapierre, Sudharshan Eathiraj, Nivedita Namdev, Brian Schwartz, Yusuke Ota, Takayuki Momose, Tomoyuki Tsunemi, Hiroaki Inagaki, Kiyoshi Nakayama
  • RAD51 INHIBITORS
    Publication number: 20200291014
    Abstract: This application is directed to inhibitors of RAD51 represented by the following structural formula, and methods for their use, such as to treat cancer, autoimmune diseases, immune deficiencies, or neurodegenerative diseases.
    Type: Application
    Filed: March 12, 2020
    Publication date: September 17, 2020
    Inventors: Jean-Marc LAPIERRE, Casey Cameron MCCOMAS, Joseph VACCA
  • TETRAHYDROPYRANYL AMINO-PYRROLOPYRIMIDINONE AND METHODS OF USE THEREOF
    Publication number: 20200061071
    Abstract: The application relates to a compound of Formula (I): or a pharmaceutically acceptable salt thereof, tautomer, prodrug, solvate, metabolite, polymorph, analog or derivative thereof, which modulates the activity of BTK, a pharmaceutical composition comprising the compound of Formula (I), and a method of treating or preventing a disease in which BTK plays a role.
    Type: Application
    Filed: November 4, 2019
    Publication date: February 27, 2020
    Inventors: Jean-Marc LAPIERRE, Sudharshan EATHIRAJ, Nivedita NAMDEV, Brian SCHWARTZ, Yusuke OTA, Takayuki MOMOSE, Tomoyuki TSUNEMI, Hiroaki INAGAKI, Kiyoshi NAKAYAMA
  • AMINO-PYRROLOPYRIMIDINONE COMPOUNDS AND METHODS OF USE THEREOF
    Publication number: 20190358233
    Abstract: The application relates to a compound of Formula (I): or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, which modulates the activity of BTK, a pharmaceutical composition comprising a compound of Formula (I), and a method of treating or preventing a disease in which BTK plays a role.
    Type: Application
    Filed: August 5, 2019
    Publication date: November 28, 2019
    Inventors: Craig BATES, Sudharshan Eathiraj, Hiroaki Inagaki, Jean-Marc Lapierre, Takayuki Momose, Kiyoshi Nakayama, Takashi Odagiri, Masahiro Ota, Yusuke Ota, Yoshihiro Shibata, Manish Tandon, Tomoyuki Tsunemi
  • TETRAHYDROPYRANYL AMINO-PYRROLOPYRIMIDINONE AND METHODS OF USE THEREOF
    Publication number: 20190192520
    Abstract: The application relates to a compound of Formula (I): or a pharmaceutically acceptable salt thereof, tautomer, prodrug, solvate, metabolite, polymorph, analog or derivative thereof, which modulates the activity of BTK, a pharmaceutical composition comprising the compound of Formula (I), and a method of treating or preventing a disease in which BTK plays a role.
    Type: Application
    Filed: March 4, 2019
    Publication date: June 27, 2019
    Inventors: Jean-Marc LAPIERRE, Sudharshan EATHIRAJ, Nivedita NAMDEV, Brian SCHWARTZ, Yusuke OTA, Takayuki MOMOSE, Tomoyuki TSUNEMI, Hiroaki INAGAKI, Kiyoshi NAKAYAMA
  • Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof
    Patent number: 10245263
    Abstract: The application relates to a compound of Formula (I): or a pharmaceutically acceptable salt thereof, tautomer, prodrug, solvate, metabolite, polymorph, analog or derivative thereof, which modulates the activity of BTK, a pharmaceutical composition comprising the compound of Formula (I), and a method of treating or preventing a disease in which BTK plays a role.
    Type: Grant
    Filed: March 3, 2017
    Date of Patent: April 2, 2019
    Assignee: ArQule, Inc.
    Inventors: Jean-Marc Lapierre, Sudharshan Eathiraj, Nivedita Namdev, Brian Schwartz, Yusuke Ota, Takayuki Momose, Tomoyuki Tsunemi, Hiroaki Inagaki, Kiyoshi Nakayama
  • Compositions and methods for treating proliferation disorders
    Patent number: 9949981
    Abstract: The present invention relates to methods of treating cell proliferative disorders, such as cancer or Proteus syndrome, by utilizing 3-(3-(4-(1-aminocyclobutyl)phenyl)-5-phenyl-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amine or 3-(3-(4-(1-aminocyclobutyl)phenyl)-5-(3-morpholinophenyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amine or N-(1-(3-(3-(4-(1-aminocyclobutyl)phenyl)-2-(2-aminopyridin-3-yl)-3H-imidazo[4,5-b]pyridin-5-yl)phenyl)piperidin-4-yl)-N-methylacetamide. The methods of the present invention can also relate to methods of treating cell proliferative disorders, such as cancer or Proteus syndrome, by utilizing the above compounds in combination with ((R)-6-(2-fluorophenyl)-N-(3-(2-((2-methoxyethyl)amino)ethyl)phenyl)-5,6-dihydrobenzo[h]quinazolin-2-amine).
    Type: Grant
    Filed: September 4, 2015
    Date of Patent: April 24, 2018
    Assignee: ArQule, Inc.
    Inventors: Daniel T. Dransfield, Sudharshan Eathiraj, Jean-Marc Lapierre, Brian Schwartz, Yi Yu
  • AMINO-PYRROLOPYRIMIDINONE COMPOUNDS AND METHODS OF USE THEREOF
    Publication number: 20180055846
    Abstract: The application relates to a compound of Formula (I): or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, which modulates the activity of BTK, a pharmaceutical composition comprising a compound of Formula (I), and a method of treating or preventing a disease in which BTK plays a role.
    Type: Application
    Filed: August 23, 2017
    Publication date: March 1, 2018
    Inventors: Craig BATES, Sudharshan Eathiraj, Hiroaki Inagaki, Jean-Marc Lapierre, Takayuki Momose, Kiyoshi Nakayama, Takashi Odagiri, Masahiro Ota, Yusuke Ota, Yoshihiro Shibata, Manish Tandon, Tomoyuki Tsunemi
  • TETRAHYDROPYRANYL AMINO-PYRROLOPYRIMIDINONE AND METHODS OF USE THEREOF
    Publication number: 20170182053
    Abstract: The application relates to a compound of Formula (I): or a pharmaceutically acceptable salt thereof, tautomer, prodrug, solvate, metabolite, polymorph, analog or derivative thereof, which modulates the activity of BTK, a pharmaceutical composition comprising the compound of Formula (I), and a method of treating or preventing a disease in which BTK plays a role.
    Type: Application
    Filed: March 3, 2017
    Publication date: June 29, 2017
    Inventors: Jean-Marc LAPIERRE, Sudharshan EATHIRAJ, Nivedita NAMDEV, Brian SCHWARTZ, Yusuke OTA, Takayuki MOMOSE, Tomoyuki TSUNEMI, Hiroaki INAGAKI, Kiyoshi NAKAYAMA
  • Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof
    Patent number: 9630968
    Abstract: The application relates to a compound of Formula (I): or a pharmaceutically acceptable salt thereof, tautomer, prodrug, solvate, metabolite, polymorph, analog or derivative thereof, which modulates the activity of BTK, a pharmaceutical composition comprising the compound of Formula (I), and a method of treating or preventing a disease in which BTK plays a role.
    Type: Grant
    Filed: December 23, 2015
    Date of Patent: April 25, 2017
    Assignee: ArQule, Inc.
    Inventors: Jean-Marc Lapierre, Sudharshan Eathiraj, Nivedita Namdev, Brian Schwartz, Yusuke Ota, Takayuki Momose, Tomoyuki Tsunemi, Hiroaki Inagaki, Kiyoshi Nakayama
  • Compositions and Methods for Treating Proliferation Disorders
    Publication number: 20160067260
    Abstract: The present invention relates to methods of treating cell proliferative disorders, such as cancer or Proteus syndrome, by utilizing 3-(3-(4-(1-aminocyclobutyl)phenyl)-5-phenyl-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amine or 3-(3-(4-(1-aminocyclobutyl)phenyl)-5-(3-morpholinophenyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amine or N-(1-(3-(3-(4-(1-aminocyclobutyl)phenyl)-2-(2-aminopyridin-3-yl)-3H-imidazo[4,5-b]pyridin-5-yl)phenyl)piperidin-4-yl)-N-methylacetamide. The methods of the present invention can also relate to methods of treating cell proliferative disorders, such as cancer or Proteus syndrome, by utilizing the above compounds in combination with ((R)-6-(2-fluorophenyl)-N-(3-(2-((2-methoxyethyl)amino)ethyl)phenyl)-5,6-dihydrobenzo[h]quinazolin-2-amine).
    Type: Application
    Filed: September 4, 2015
    Publication date: March 10, 2016
    Inventors: Daniel T. Dransfield, Sudharshan Eathiraj, Jean-Marc Lapierre, Brian Schwartz, Yi Yu